))
The Hurdles of Insuring Patients with Nano-rare Mutations with Alan Lotvin, M.D.
Manage episode 420922541 series 3349924
内容由n-Lorem Foundation and N-Lorem Foundation提供。所有播客内容（包括剧集、图形和播客描述）均由 n-Lorem Foundation and N-Lorem Foundation 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品，您可以按照此处概述的流程进行操作https://zh.player.fm/legal。
What's preventing insurers from covering the specialized care of patients with nano-rare mutations, thereby expanding access to available treatment options? Is it the population size, cost, or perceived risk? Given that the initial discovery of nano-rare mutations is relatively recent, paving the way for this population requires a nuanced approach to overcome various obstacles. Alan Lotvin, M.D., CEO and co-founder of Sequel Med Tech, and former president of CVS Caremark, conceptualizes these hurdles.
55集单集
分享
